Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1A | P35348 | 16/20 | 0.67 |
| ▸ | HRH1 | P35367 | 16/20 | 0.67 |
| ▸ | ADRA1B | P35368 | 16/20 | 0.67 |
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.67 |
| ▸ | KCNH2 | Q12809 | 13/20 | 0.67 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2434621 | 1.00 | ADRA1A (0.67) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| SCHEMBL2429351 | 0.88 | ADRA1A (0.66) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| SCHEMBL2430475 | 0.88 | ADRA1A (0.66) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| SCHEMBL4791221 | 0.88 | ADRA1A (0.66) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| SCHEMBL2430003 | 0.77 | ADRA1A (0.81) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| SCHEMBL2425882 | 0.77 | ADRA1A (0.82) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| SCHEMBL2996924 | 0.76 | ADRA1A (0.84) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| SCHEMBL2994321 | 0.76 | HRH1 (0.78) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| SCHEMBL2428427 | 0.75 | ADRA1A (0.84) | ADRA1AHRH1ADRA1BHRH3KCNH2 | |
| SCHEMBL2819425 | 0.75 | HRH1 (0.69) | ADRA1AHRH1ADRA1BHRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105225-A1 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists | GLAXO GROUP LIMITED (GB) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105225-A1 | 2-Substituted 4-Benzylphthalazinone Derivatives as Histamine H1 and H3 Antagonists | HRH2, HRH3, HRH4 | ADRA1A 150/4885HRH1 4/4885ADRA1B 134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.